Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 20/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29233356 | 1.00 | USP1 (0.41) | USP1 | |
| SCHEMBL30939412 | 0.87 | USP1 (0.38) | USP1 | |
| SCHEMBL29233355 | 0.87 | USP1 (0.38) | USP1 | |
| SCHEMBL26442519 | 0.83 | USP1 (0.44) | USP1 | |
| SCHEMBL30816562 | 0.81 | USP1 (0.44) | USP1 | |
| SCHEMBL30966307 | 0.80 | USP1 (0.43) | USP1 | |
| SCHEMBL30966290 | 0.78 | USP1 (0.48) | USP1 | |
| SCHEMBL22122099 | 0.75 | USP1 (0.46) | USP1 | |
| SCHEMBL18865620 | 0.74 | USP1 (0.48) | USP1 | |
| SCHEMBL21821550 | 0.73 | USP1 (0.42) | USP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118215664-B | Substituted triazoloheteroaryl compounds as USP1 inhibitors and uses thereof | 上海瑛派药业有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20240409538-A1 | SUBSTITUTED TRIAZOLOHETEROARYL COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-4419522-A1 | SUBSTITUTED TRIAZOLOHETEROARYL COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2024-08-28 | — | — | EP | disclosed |
| CN-118215664-A | Substituted triazoloheteroaryl compounds as USP1 inhibitors and uses thereof | 上海瑛派药业有限公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2023066299-A1 | SUBSTITUTED TRIAZOLOHETEROARYL COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409538-A1 | SUBSTITUTED TRIAZOLOHETEROARYL COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | USP1, USP2, USP3 | USP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.